The cryptococcus neoformans cap10 and cap59 mutant strains, affected in glucuronoxylomannan synthesis, differentially activate human dendritic cells

FEMS Immunology and Medical Microbiology

Volumn 57, Issue 2, 2009, Pages 142-150

  Grijpstra, Jan ^a   Tefsen, Boris ^b   Van Die, Irma ^b   De Cock, Hans ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Capsule; Cryptococcus; Dendritic cell; Immune evasion; Polysaccharide

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; GLUCURONOXYLOMANNAN; INTERLEUKIN 10; INTERLEUKIN 12P40; TUMOR NECROSIS FACTOR ALPHA; VIRULENCE FACTOR;

ANTIGEN EXPRESSION; ARTICLE; CARBOHYDRATE SYNTHESIS; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIUM; CYTOKINE PRODUCTION; DENDRITIC CELL; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS CULTURE; FUNGUS MUTANT; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANTIGENS, CD80; ANTIGENS, CD86; CELL DIFFERENTIATION; CELLS, CULTURED; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIA, CONDITIONED; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; FUNGAL PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; POLYSACCHARIDES;

EID: 70349686684     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2009.00587.x     Document Type: Article

References (43)

1. Akira S, Uematsu S Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124 : 783 801.
2. Banchereau J Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392 : 245 252.
3. Bretaudeau K, Eloy O, Richer A, Bruneel F, Scott-Algara D, Lortholary O Pico F (2006) Cryptococcal meningo-encephalitis in an apparently immunocompetent patient. Rev Neurol 162 : 233 237.
4. Buchanan KL Murphy JW (1998) What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis 4 : 71 83.
5. Chang YC Kwon-Chung KJ (1994) Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 14 : 4912 4919.
6. Chang YC Kwon-Chung KJ (1998) Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans. Infect Immun 66 : 2230 2236.
7. Chang YC Kwon-Chung KJ (1999) Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans. J Bacteriol 181 : 5636 5643.
8. Chang YC, Penoyer LA Kwon-Chung KJ (1996) The second capsule gene of Cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun 64 : 1977 1983.
9. Cherniak R Sundstrom JB (1994) Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun 62 : 1507 1512.
10. Cherniak R, Reiss E Turner SH (1982) A galactoxylomannan antigen of Cryptococcus neoformans serotype. Carbohyd Res 103 : 239 250.
11. Cherniak R, Jones RG Reiss E (1988) Structure determination of Cryptococcus neoformans serotype A-variant glucuronoxylomannan by 13C-n.m.r. spectroscopy. Carbohyd Res 172 : 113 138.
12. Chute HL, Davis FL Payne DD (1965) Cryptococcosis, a disease of man and animals. J Maine Med Assoc 56 : 228 229.
13. Doering TL (2000) How does Cryptococcus get its coat? Trends Microbiol 8 : 547 553.
14. Franzot SP, Salkin IF Casadevall A (1999) Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 37 : 838 840.
15. Geijtenbeek TB, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CM, Appelmelk B Van Kooyk Y (2003) Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 197 : 7 17.
16. Grijpstra J, Gerwig GJ, Wosten H, Kamerling JP de Cock H (2009) Production of extracellular polysaccharides by cap mutants of Cryptococcus neoformans. Eukaryot Cell 8 : 1165 1173.
17. Hamilton AJ Goodley J (1996) Virulence factors of Cryptococcus neoformans. Curr Top Med Mycol 7 : 19 42.
18. Kidd SE, Hagen F, Tscharke RL et al 2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). P Natl Acad Sci USA 101 : 17258 17263.
19. Klutts JS Doering TL (2008) Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides. J Biol Chem 238 : 14327 14334.
20. Klutts JS, Levery SB Doering TL (2007) A beta-1,2 xylosyltranferase from Cryptococcus neoformans defines a new family of glycosyltransferases. J Biol Chem 282 : 17890 17899.
21. Kozel TR (1995) Virulence factors of Cryptococcus neoformans. Trends Microbiol 3 : 295 299.
22. Levitz SM (1991) The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 13 : 1163 1169.
23. Levitz SM Specht CA (2006) The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res 6 : 513 524.
24. Lui G, Lee N, Ip M et al 2006) Cryptococcosis in apparently immunocompetent patients. Q J Med 99 : 143 151.
25. Lupo P, Chang YC, Kelsall BL et al 2008) The presence of capsule in Cryptococcus neoformans influences the gene expression profile in dendritic cells during interaction with the fungus. Infect Immun 76 : 1581 1589.
26. Mansour MK, Latz E Levitz SM (2006) Cryptococcus neoformans glycoantigens are captured by multiple lectin receptors and presented by dendritic cells. J Immunol 176 : 3053 3061.
27. Maxson ME, Cook E, Casadevall A Zaragoza O (2006) The volume and hydration of the Cryptococcus neoformans polysaccharide capsule. Fungal Genet Biol 44 : 180 186.
28. Moyrand F Janbon G (2004) UGD1, encoding the Cryptococcus neoformans UDP-glucose dehydrogenase, is essential for growth at 37 °C and for capsule biosynthesis. Eukaryot Cell 3 : 1601 1608.
29. Murphy JW (1999) Immunological down-regulation of host defenses in fungal infections. Mycoses 42 (suppl 2) : 37 43.
30. Nakamura K, Miyazato A, Xiao G et al 2008) Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway. J Immunol 180 : 4067 4074.
31. Perfect JR, Wong B, Chang YC, Kwon-Chung KJ Williamson PR (1998) Cryptococcus neoformans: virulence and host defences. Med Mycol 36 (suppl 1) : 79 86.
32. Pietrella D, Corbucci C, Perito S, Bistoni G Vecchiarelli A (2005) Mannoproteins from Cryptococcus neoformans promote dendritic cell maturation and activation. Infect Immun 73 : 820 827.
33. Reese AJ Doering TL (2003) Cell wall alpha-1,3-glucan is required to anchor the Cryptococcus neoformans capsule. Mol Microbiol 50 : 1401 1409.
34. Reiss E, Huppert M Cherniak R (1985) Characterization of protein and mannan polysaccharide antigens of yeasts, moulds, and actinomycetes. Curr Top Med Mycol 1 : 172 207.
35. Sallusto F Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179 : 1109 1118.
36. Siegemund S Alber G (2008) Cryptococcus neoformans activates bone marrow-derived conventional dendritic cells rather than plasmacytoid dendritic cells and down-regulates macrophages. FEMS Immunol Med Mic 52 : 417 427.
37. Sommer U, Liu H Doering TL (2003) An alpha-1,3-mannosyltransferase of Cryptococcus neoformans. J Biol Chem 278 : 47724 47730.
38. Syme RM, Spurrell JC, Amankwah EK, Green FH Mody CH (2002) Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcγ receptor II for presentation to T lymphocytes. Infect Immun 70 : 5972 5981.
39. van Liempt E, van Vliet SJ, Engering A et al 2007) Schistosoma mansoni soluble egg antigens are internalized by human dendritic cells through multiple C-type lectins and suppress TLR-induced dendritic cell activation. Mol Immunol 44 : 2605 2615.
40. van Vliet SJ, den Dunnen J, Gringhuis SI, Geijtenbeek TB van Kooyk Y (2007) Innate signaling and regulation of dendritic cell immunity. Curr Opin Immunol 19 : 435 440.
41. Vecchiarelli A, Pietrella D, Lupo P, Bistoni F, McFadden DC Casadevall A (2003) The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation. J Leukocyte Biol 74 : 370 378.
42. Yauch LE, Lam JS Levitz SM (2006) Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan. PLoS Pathog 2 : e120.
43. Zebedee SL, Koduri RK, Mukherjee J et al 1994) Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Ch 38 : 1507 1514.